PMID- 30155805
OWN - NLM
STAT- MEDLINE
DCOM- 20190114
LR  - 20190114
IS  - 1573-6903 (Electronic)
IS  - 0364-3190 (Linking)
VI  - 43
IP  - 10
DP  - 2018 Oct
TI  - Effects of NMDAR Antagonist on the Regulation of P-MARCKS Protein to Abeta(1-42) 
      Oligomers Induced Neurotoxicity.
PG  - 2008-2015
LID - 10.1007/s11064-018-2622-8 [doi]
AB  - Alzheimer's disease (AD) is a well-known neurodegenerative disease. Deposition of 
      beta-amyloid protein (Abeta) oligomers plays a crucial role in the disease progression. 
      Previous studies showed that toxicity induced by Abeta oligomers in cultured neurons 
      and adult rat brain was partially mediated by activation of glutamatergic 
      N-methyl-D-aspartate receptors (NMDAR). Additionally, memantine, a noncompetitive 
      NMDAR antagonist, can significantly improve cognitive functions in some AD 
      patients. However, little is currently known about the potential role of NMDAR 
      antagonist on the regulation of P-MARCKS protein to Abeta(1-42) oligomers induced 
      neurotoxicity. The protective effect and mechanism of NMDAR antagonist on primary 
      neurons exposed to Abeta(1-42) oligomers were investigated in the study. We have 
      defined that the Abeta(1-42) treatment decreased cell viability and increased 
      apoptosis. Moreover, Abeta(1-42) oligomers exposure increased P-MARCKS and PIP2 
      expressions, while decreased SYP expression. However, NMDAR antagonist 
      pretreatment ameliorates Abeta(1-42) oligomers induced neuronal apoptosis and 
      partially reverses the expression of P-MARCKS, PIP2 and SYP. In conclusion, NMDAR 
      antagonist may ameliorate neurotoxicity induced by Abeta(1-42) oligomers through 
      reducing neuronal apoptosis and protecting synaptic plasticity in rat primary 
      neurons. The mechanism involved may be mediated by the variation of protein 
      P-MARCKS.
FAU - Liu, Yudong
AU  - Liu Y
AD  - Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, People's Republic of China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, People's Republic of China.
FAU - Zheng, Yabing
AU  - Zheng Y
AD  - Central Laboratory, Shandong Provincial Qianfoshan Hospital, Shandong University, 
      Jinan, 250014, People's Republic of China.
FAU - Yang, Chunlin
AU  - Yang C
AD  - Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, People's Republic of China.
FAU - Du, Tong
AU  - Du T
AD  - Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, People's Republic of China.
FAU - Ge, Mengru
AU  - Ge M
AD  - Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, People's Republic of China.
FAU - Chang, Xiaotian
AU  - Chang X
AD  - Central Laboratory, Shandong Provincial Qianfoshan Hospital, Shandong University, 
      Jinan, 250014, People's Republic of China.
FAU - Duan, Ruisheng
AU  - Duan R
AD  - Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, People's Republic of China.
FAU - Ma, Guozhao
AU  - Ma G
AD  - Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, People's Republic of China. maguozhao@163.com.
LA  - eng
GR  - 30600202/National Natural Science Foundation of China (CN)/
GR  - 30710303072/National Natural Science Foundation of China (CN)/
GR  - 30870874/National Natural Science Foundation of China (CN)/
PT  - Journal Article
DEP - 20180828
PL  - United States
TA  - Neurochem Res
JT  - Neurochemical research
JID - 7613461
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 125267-21-2 (Myristoylated Alanine-Rich C Kinase Substrate)
SB  - IM
MH  - Alzheimer Disease/metabolism
MH  - Amyloid beta-Peptides/*toxicity
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Female
MH  - Male
MH  - Myristoylated Alanine-Rich C Kinase Substrate/*drug effects
MH  - Neurons/*drug effects/metabolism
MH  - Neuroprotective Agents/pharmacology
MH  - Neurotoxicity Syndromes/metabolism
MH  - Peptide Fragments/toxicity
MH  - Rats
MH  - Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors/metabolism
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Abeta1-42 oligomers
OT  - Cell apoptosis
OT  - P-MARCKS
OT  - Synaptic plasticity
EDAT- 2018/08/30 06:00
MHDA- 2019/01/15 06:00
CRDT- 2018/08/30 06:00
PHST- 2018/05/22 00:00 [received]
PHST- 2018/08/21 00:00 [accepted]
PHST- 2018/08/19 00:00 [revised]
PHST- 2018/08/30 06:00 [pubmed]
PHST- 2019/01/15 06:00 [medline]
PHST- 2018/08/30 06:00 [entrez]
AID - 10.1007/s11064-018-2622-8 [pii]
AID - 10.1007/s11064-018-2622-8 [doi]
PST - ppublish
SO  - Neurochem Res. 2018 Oct;43(10):2008-2015. doi: 10.1007/s11064-018-2622-8. Epub 
      2018 Aug 28.